Capecitabine before surgery for head and neck cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Lungs & breathing, Mouth & dental clinical trials.
This trial tests whether giving the chemotherapy drug capecitabine (Xeloda) before surgery helps shrink head and neck cancers that are not linked to HPV. It is for people with early to moderately advanced disease who have not yet had any treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a newly diagnosed head and neck cancer that is not caused by HPV (human papillomavirus).
- Your cancer is at an early or moderately advanced stage (Stage I, II, III, or IVA) and has not spread to distant parts of the body.
- You are able to undergo surgery and have a good performance status (able to carry out daily activities with little or no help).
- You are not pregnant, breastfeeding, or planning to become pregnant, and you agree to use contraception if needed.
- You do not have a known allergy to capecitabine or a genetic condition called DPYD deficiency.
- You have not had previous cancer treatment for this illness, and you do not have another active cancer that requires treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking capecitabine pills on a steady, low schedule after standard treatment can help keep locally advanced head and neck squamous cell cancer from coming back or spreading. You may be eligible if your cancer is stage III–IV and you have finished certain radiation/chemo treatments on time, without current spread.
This study tests whether low-dose capecitabine given after standard treatment can lower the chance that locoregional (nearby) throat cancer returns. It is designed for adults with advanced hypopharyngeal (throat) cancer who have finished curative chemoradiation or surgery and follow-up therapy and show no active cancer on exam.
This Phase 3 study tests whether adding capecitabine (a chemotherapy pill) after breast cancer surgery can lower the chance the cancer comes back. It targets people with hormone-receptor–positive and HER2-negative breast cancer who are considered “high risk.”
This trial looks at whether adding a chemotherapy medicine called capecitabine (taken in smaller, regular doses) to the standard after-surgery (adjuvant) treatment can lower the chance of cancer coming back in people with early-stage, high-risk HER2-positive breast cancer. It targets patients who still had cancer left after earlier treatment or who had higher-risk tumor features.
This study compares taking capecitabine pills after curative surgery versus no further treatment. It aims to lower the chance of stomach cancer coming back in people with stage IB disease that has extra risk factors.
This trial tests a combination of three drugs (tirelizumab, carboplatin, and a special form of paclitaxel) given before surgery to treat advanced head and neck cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
Hear when a new Mouth Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.